Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 4, 2025 | Baird Small/Mid Cap Growth Equity Fund | 4.5% | -6.6% | ADMA, ALAB, ALHC, BJ, BMI, BOOT, BRBR, BWXT, CASY, CAVA, CHDN, COCO, CWAN, DKNG, DSGX, ELF, EQH, EXLS, FDS, FND, FOUR, FSS, GLOB, HLI, HQY, INSM, INSP, KAI, KNSL, LII, MANH, MKTX, MNDY, MTSI, NBIX, ONTO, PODD, PSTG, SPSC, SRPT, SSD, TARS, TECH, TREX, ULS, VERX, WAY, WSC, WSO, XPEL | AI, Biotech, growth, healthcare, semiconductors, small cap, technology, underperformance | The benchmark's rally was led by companies with AI-exposure that drove rapid multiple expansion. The portfolio underperformed due to underexposure to more speculative AI areas including small cap semiconductors and AI-hardware. Defensive positions with minimal AI-exposure were the largest detractors to relative performance. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | Fund Letters | Eric Mintz | Sarepta Therapeutics, Inc. | Health Care | Biotechnology | Bear | NASDAQ | Biotech, gene therapy, Neuromuscular, Regulation, Risk | View Pitch |
| Aug 7, 2025 | Seeking Alpha | Tradevestor | Sarepta Therapeutics, Inc. | Health Care | Biotechnology | Bull | NASDAQ | — | View Pitch |
| Aug 7, 2025 | Seeking Alpha | Edmund Ingham | Sarepta Therapeutics, Inc. | Health Care | Biotechnology | Bear | NASDAQ | — | View Pitch |
| Aug 7, 2025 | Seeking Alpha | Terry Chrisomalis | Sarepta Therapeutics, Inc. | Health Care | Biotechnology | Bear | NASDAQ | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| Paul Tudor Jones | Tudor Investment Corp | $53.4B | $387,360 | 0.00% | 18,000 | -329,400 | -94.82% | 0.0200% |
| Steven A. Cohen | Point72 Asset Management | $86.8B | $4.5M | 0.01% | 207,513 | +157,513 | +315.03% | 0.2307% |
| Ray Dalio | Bridgewater Associates | $27.4B | $6.0M | 0.02% | 280,568 | -71,707 | -20.36% | 0.3120% |
| Dmitry Balyasny | Balyasny Asset Management | $76.6B | $2.0M | 0.00% | 91,619 | -233,000 | -60.84% | 0.1019% |
| Israel Englander | Millennium Management LLC | $233.2B | $21.5M | 0.01% | 1,000,109 | +715,899 | +251.89% | 1.1120% |
| David Siegel & John Overdeck | Two Sigma Investments | $67.5B | $52.5M | 0.08% | 2,441,455 | +303,691 | +14.21% | 2.7147% |
| Cliff Asness | AQR Capital Management | $190.6B | $167.8M | 0.09% | 7,796,535 | +6,390,860 | +454.65% | 8.6690% |